» Articles » PMID: 2543282

In Vitro Synergism Between Daptomycin and Fosfomycin Against Enterococcus Faecalis Isolates with High-level Gentamicin Resistance

Overview
Specialty Pharmacology
Date 1989 Apr 1
PMID 2543282
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Daptomycin and fosfomycin are two agents which inhibit different steps in peptidoglycan synthesis. We studied the in vitro activities of these drugs, alone and in combination, by time-kill techniques against 21 clinical isolates of Enterococcus (Streptococcus) faecalis demonstrating high-level resistance to gentamicin. Combinations of fosfomycin and daptomycin exhibited synergistic bactericidal activity (100-fold decrease in CFU per milliliter at 24 h compared with daptomycin alone) against all strains (mean +/- standard deviation of increment in killing = 2.7 +/- 0.7 log10 CFU/ml). In a subgroup of strains against which daptomycin (5 micrograms/ml) alone was bactericidal (greater than 3 log10 killing), synergistic activity was demonstrable only when the concentration of daptomycin was lowered to 0.25 to 0.5 microgram/ml. A 50% dilution of human serum diminished the bactericidal activity of daptomycin alone at 24 h but did not affect killing observed with the daptomycin-fosfomycin combination. The inhibition of peptidoglycan synthesis by the combination was greater than the inhibition observed with either drug alone. The combination of daptomycin and fosfomycin exhibited consistent synergistic bactericidal activity against strains of E. faecalis possessing high-level resistance to gentamicin. This synergism may be the result of sequential inhibition of early steps in peptidoglycan synthesis.

Citing Articles

From Isolation to Application: Utilising Phage-Antibiotic Synergy in Murine Bacteremia Model to Combat Multidrug-Resistant Enterococcus faecalis.

Yehia F, Yahya G, Elsayed E, Serrania J, Becker A, Gomaa S Microb Biotechnol. 2025; 18(1):e70075.

PMID: 39801028 PMC: 11725608. DOI: 10.1111/1751-7915.70075.


Treatment of Infective Endocarditis: A Continuing Challenge.

Herrera-Hidalgo L, Fernandez-Rubio B, Luque-Marquez R, Lopez-Cortes L, Gil-Navarro M, de Alarcon A Antibiotics (Basel). 2023; 12(4).

PMID: 37107066 PMC: 10135260. DOI: 10.3390/antibiotics12040704.


Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies.

Antonello R, Principe L, Maraolo A, Viaggi V, Pol R, Fabbiani M Antibiotics (Basel). 2020; 9(8).

PMID: 32785114 PMC: 7460049. DOI: 10.3390/antibiotics9080500.


A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.

Beganovic M, Luther M, Rice L, Arias C, Rybak M, LaPlante K Clin Infect Dis. 2018; 67(2):303-309.

PMID: 29390132 PMC: 6248357. DOI: 10.1093/cid/ciy064.


Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention.

Benamu E, Deresinski S F1000Res. 2018; 7:3.

PMID: 29333263 PMC: 5750719. DOI: 10.12688/f1000research.11831.1.


References
1.
Wessler S . Enterococcal endocarditis. JAMA. 1968; 204(10):916-21. View

2.
Bush L, Boscia J, Kaye D . Daptomycin (LY146032) treatment of experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1988; 32(6):877-81. PMC: 172299. DOI: 10.1128/AAC.32.6.877. View

3.
Lugtenberg E, DE HAAN P . A simple method for following the fate of alanine-containing components in murein synthesis in Escherichia coli. Antonie Van Leeuwenhoek. 1971; 37(4):537-52. DOI: 10.1007/BF02218524. View

4.
KAHAN F, Kahan J, Cassidy P, KROPP H . The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci. 1974; 235(0):364-86. DOI: 10.1111/j.1749-6632.1974.tb43277.x. View

5.
Fujii R . Fosfomycin in the treatment of bacterial infections: summary of clinical trials in Japan. Chemotherapy. 1977; 23 Suppl 1:234-46. DOI: 10.1159/000222054. View